Mycophenolate Mofetil Accord

Mycophenolate Mofetil, the active ingredient in Mycophenolate Mofetil Accord, is an immunosuppressant presented as an oral formulation for oral use. It is employed to prevent rejection of transplanted organs and to treat selected autoimmune disorders such as lupus nephritis in adult patients under specialist supervision.

GNH USA supplies Mycophenolate Mofetil Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide, with a focus on quality assurance, regulatory compliance and reliable cold‑chain logistics where required and timely delivery.

Mycophenolate Mofetil is used as an immunosuppressive agent to control immune‑mediated rejection and autoimmunity.

Kidney transplant: helps maintain graft function and reduces acute rejection episodes. Heart transplant: lowers risk of organ rejection and improves long‑term survival. Liver transplant: prevents immune‑driven graft injury and supports transplant success. Lupus nephritis: reduces renal inflammation and slows disease progression. Pancreas transplant: decreases incidence of rejection and preserves endocrine function.

Mycophenolate Mofetil may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea - Diarrhea - Headache - Abdominal pain - Vomiting - Upper respiratory tract infections

Serious or Rare Side Effects: - Bone marrow suppression leading to anemia, leukopenia or thrombocytopenia - Severe opportunistic infections, including fungal and viral pathogens - Progressive multifocal leukoencephalopathy (PML) - Hepatic toxicity with elevated transaminases - Teratogenic effects causing fetal malformations - Malignancies such as post‑transplant lymphoproliferative disorder

When prescribing Mycophenolate Mofetil, clinicians should observe several safety measures.

Monitor blood counts: perform regular complete blood count to detect marrow suppression. Assess renal function: check serum creatinine and eGFR periodically. Evaluate liver enzymes: monitor hepatic transaminases for potential toxicity. Avoid use in pregnancy: drug is contraindicated due to high teratogenic risk. Limit live vaccines: patients should not receive live attenuated vaccines while on therapy. Store at below 25°C: keep in original container, protect from moisture and heat.

Mycophenolate Mofetil interacts with several medicines that can alter its exposure or increase toxicity.

Major Interactions (Avoid): - Azathioprine: additive bone‑marrow suppression. - Rifampin: induces metabolism, markedly reducing drug levels. - Antacids containing aluminum or magnesium: decrease oral absorption. - Cholestyramine or other bile‑acid sequestrants: bind drug and lower bioavailability. - Live vaccines: increase risk of severe infection.

Moderate Interactions (Monitor Closely): - Cyclosporine or tacrolimus: may increase mycophenolate exposure; dose adjustment may be required. - ACE inhibitors or ARBs: combined use may affect renal function; monitor creatinine. - NSAIDs: can worsen renal impairment; check kidney parameters.